Nephrocare Health Services · forward-looking guidance across the available source record.
Guidance tracker
Management explicitly declined annual guidance, stating the third growth driver (acquisitions, large PPPs, new country entries) is unpredictable. They cautioned investors not to extrapolate Q3's exceptional results (32% growth) as representative of future quarters.
Margins expected to remain around current levels. New geographic entries may initially pull margins down by 1-1.5% (100-150bps), but operating leverage in existing geographies offsets this. Management declined specific annual margin guidance.
JV with publicly listed Tibia is in license acquisition stage for captive unit at Riyad Hospital. Revenue expected to start in 'a few quarters' as the company demonstrates capabilities before scaling.
Historical annual capital expenditure ranges from 100-125 crore, though management noted difficulty predicting future numbers. All investments evaluated on Return on Sales (ROSI) criteria.